Biote’s shares gained 11.8% following a quarter marked by a voluntary product recall that disrupted sales but highlighted progress in commercial expansion and practitioner engagement, suggesting improving fundamentals despite near-term headwinds.

• Revenue declined 8.3% to $44.9 million, with procedure revenue down 13.2%, partly due to a $1.7 million impact from a voluntary hormone pellet recall.
• The recall also caused approximately $1.5 million in incremental costs and distracted the sales force from growth initiatives.
• Biote expanded its sales team substantially, adding over 25 new sales personnel in Q1 2026, now nearing the targeted 120 total.
• Training of new practitioners increased 16.5% year-over-year, signaling strong future growth potential given typical six-month lag to contribution.
• Management emphasized a more disciplined sales pipeline focus on higher-value OB/GYN and general practitioners, aiming for more predictable revenue streams.